InvestSMART

PharmAust Limited (ASX: PAA) - Announcements

Current share price for PAA : $0.230 0.015 (6.98%)+

ASX company news and announcements for PharmAust Limited (PAA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PharmAust Limited (PAA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PharmAust Limited (PAA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PharmAust Limited (PAA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Reformulated MPL capsules completed, Phase II to commence 11 Jul 2016 8:25AM $0.085 $0.230 risen by 170.59%
- University of Cambridge to begin Phase II Trial 27 Jun 2016 8:24AM $0.081 $0.230 risen by 183.95%
- Epichem Successful in AusTrade Grant 16 Jun 2016 8:22AM $0.089 $0.230 risen by 158.43%
- Mandate signed to raise capital in USA & list on NASDAQ 2 Jun 2016 8:23AM $0.081 $0.230 risen by 183.95%
- Appendix 4C Quarterly Report & Brief Company Update 29 Apr 2016 8:20AM $0.120 $0.230 risen by 91.67%
- RedChip issues research on PharmAust 11 Mar 2016 10:03AM $0.120 $0.230 risen by 91.67%
- Strategy for Phase II Clinical Trial of Monepantel 8 Mar 2016 8:26AM $0.120 $0.230 risen by 91.67%
- Appendix 4D & Half Yearly Report and Accounts 29 Feb 2016 8:14AM $0.110 $0.230 risen by 109.09%
- PharmAust Featured on The RedChip Money Report on Bloomberg 12 Feb 2016 11:13AM $0.096 $0.230 risen by 139.58%
- PharmAust to Present at RedChip Global Online Microcap Conf 8 Feb 2016 8:30AM $0.095 $0.230 risen by 142.11%
- Notice of Allowance received from USA Patent OffIce 5 Feb 2016 11:14AM $0.092 $0.230 risen by 150%
- PharmAust Receives $546K R&D Rebate from ATO 1 Feb 2016 2:19PM $0.095 $0.230 risen by 142.11%
- Appendix 4C - Quarterly Report & Company Update 29 Jan 2016 9:35AM $0.090 $0.230 risen by 155.56%
- USA Roadshow Presentation - January 2016 18 Jan 2016 8:26AM $0.090 $0.230 risen by 155.56%
- Juniper Pharma Services to reformulate MPL for Phase II 11 Jan 2016 8:27AM $0.110 $0.230 risen by 109.09%
- PharmAust Featured on RedChip Money Report on Bloomberg 4 Jan 2016 8:32AM $0.085 $0.230 risen by 170.59%
- Epichem Awarded Two Year Contract Extension from DNDi 21 Dec 2015 9:24AM $0.080 $0.230 risen by 187.50%
- Change of Director's Interest Notice 8 Dec 2015 8:25AM $0.075 $0.230 risen by 206.67%
- Appendix 3B & 708 Notice 4 Dec 2015 3:15PM $0.082 $0.230 risen by 180.49%
- Change of Director's Interest Notice 3 Dec 2015 3:27PM $0.084 $0.230 risen by 173.81%
- Change of Director's Interest Notice 2 Dec 2015 5:53PM $0.084 $0.230 risen by 173.81%
- GenScript Further Pre-Clinical Validation for Phase II Trial 26 Nov 2015 8:28AM $0.090 $0.230 risen by 155.56%
- RedChip appointed to begin Global Investor Relations Program 24 Nov 2015 8:25AM $0.090 $0.230 risen by 155.56%
- Change of Director's Interest Notice 6 Nov 2015 10:17AM $0.125 $0.230 risen by 84%
- Change of Director's Interest Notice 5 Nov 2015 7:38PM $0.125 $0.230 risen by 84%

551 - 575 of 796 results

Page 23 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.